We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.35
Bid: 3.30
Ask: 3.40
Change: 0.00 (0.00%)
Spread: 0.10 (3.03%)
Open: 3.35
High: 3.35
Low: 3.35
Prev. Close: 3.35
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

19 Oct 2021 12:23

RNS Number : 5525P
ValiRx PLC
19 October 2021
 

 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

ValiRx PLC

 

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify) iii:

3. Details of person subject to the notification obligation iv

Name

Adam Hargreaves

City and country of registered office (if applicable)

Cheshire, UK

4. Full name of shareholder(s) (if different from 3.) v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reached vi:

18/10/2021

6. Date on which issuer notified (DD/MM/YYYY):

19/10/2021

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

3.94%

4.21%

8.15%

5,302,452

Position of previous notification (if

applicable)

3.89%

3.78%

7.67%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

 (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB00BLH13C52

2,562,580

3.94%

GB00BLH13C52

2,739,872

4.21%

SUBTOTAL 8. A

5,302,452

8.15%

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Physical or cash

Settlement xii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

X

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Hargreaves Lansdown (Direct Holding)

3.94%

8.15%

PathCelerate Ltd. (Indirect Holding)

4.21%

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional information xvi

 

Place of completion

London, UK

Date of completion

19/10/2021

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUKUARAAURAAA
Date   Source Headline
26th Jul 20167:00 amRNSIssue of Equity and Bracknor Facility Update
14th Jul 20167:00 amRNSValiSeek Clinical Development Update
12th Jul 201611:58 amRNSResult of GM
7th Jul 20167:00 amRNSSale of TRAC Technology Rights for EUR 0.8 million
27th Jun 20167:00 amRNSNotice of GM
20th Jun 20162:24 pmRNSResult of AGM
7th Jun 20167:00 amRNSQuarterly Update
7th Jun 20167:00 amRNSAppointment of Joint Broker
26th May 20168:00 amRNSPosting of Annual Report & Notice of AGM
19th May 201611:00 amRNSFinal Results
19th May 20167:00 amRNSValiSeek Clinical Development Update
18th May 20164:45 pmRNSConversion of Loan Note, issue of warrant & equity
29th Apr 20167:00 amRNSNotification of US Patent Grant for VAL401
26th Apr 201612:07 pmRNSIssue of Equity
22nd Apr 201610:01 amRNSValiRx to exhibit at the UK Investor Show
19th Apr 20163:32 pmRNSIssue of Equity - conversion of loan note
18th Apr 20165:00 pmRNSIssue of Equity - conversion of loan note
1st Apr 20163:10 pmRNSConversion of Loan Note, issue of warrant & equity
31st Mar 20167:00 amRNSValiRx to exhibit and present at the AACR
21st Mar 20167:00 amRNSConvertible Loan Facility of up to £4.0 million
17th Mar 20167:00 amRNSValiRx engages US investor relations firm
17th Feb 20161:00 pmRNSPlacing to raise £0.5 million
16th Feb 20167:00 amRNSVAL201 Clinical Trial Update
9th Feb 20167:00 amRNSQuarterly Update on Clinical Progress
11th Dec 20159:30 amRNSValiRx to present at Shares Investor Meeting
19th Nov 201510:45 amRNSClinical Phase Development Update
5th Nov 20157:00 amRNSValiRx establishes US office in Boston, MA
27th Oct 20157:00 amRNSCollaboration Agreement
1st Oct 20157:00 amRNSNew Japanese Patent Grant
17th Sep 201512:15 pmRNSHalf Yearly Report
16th Sep 20157:00 amRNSSubscription and Equity Swap
6th Aug 20157:00 amRNSCollaboration and Research Studentship Agreement
21st Jul 20157:00 amRNSVAL201 Clinical Trial Update
16th Jul 20157:00 amRNSValiSeek Clinical Development Update
29th Jun 20157:00 amRNSGrant of options
25th Jun 20157:00 amRNSUPDATE on VAL201 Clinical Trial
3rd Jun 20157:00 amRNSChange of Adviser
27th May 201511:22 amRNSStmnt re Share Price Movement
15th May 20152:45 pmRNSResult of AGM and Capital Reorganisation
14th May 20153:50 pmRNSNotification of US Patent Grant Allowance reVAL401
14th May 20157:00 amRNSValiSeek Development Update
7th May 20157:00 amRNSRe Contract
30th Apr 20157:00 amRNSValiRX to attend 2015 BIO International Convention
22nd Apr 20157:00 amRNSNotice of AGM and Proposed Capital Reorganisation
16th Apr 20157:00 amRNSFinal Results
17th Mar 20157:00 amRNSIssue of equity to Cancer Research Technology Ltd
6th Mar 20157:00 amRNSPlacing to raise GBP800,000
26th Feb 20157:00 amRNSNew Endometriosis Patent Grant
24th Feb 20157:00 amRNSSuccessful 1st Results from VAL201 Clinical Trial
11th Feb 20157:00 amRNSNew European Patent Grant

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.